Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MAP3K14 Antibodies:
anti-Rat (Rattus) MAP3K14 Antibodies:
anti-Mouse (Murine) MAP3K14 Antibodies:
Go to our pre-filtered search.
Human Polyclonal MAP3K14 Primary Antibody for WB - ABIN392539
Bouzakri, Zierath: MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. in The Journal of biological chemistry 2007
Show all 4 Pubmed References
OLFM1 (show OLFM1 Antibodies) is a negative regulator of non-canonical NF-kappaB (show NFKB1 Antibodies) signalling by interacting with and inhibiting NIK. Thus, OLFM1 (show OLFM1 Antibodies) may serve as a valuable biomarker and therapeutic target for colorectal cancer (CRC (show CALR Antibodies)) patients.
Results reveal that endothelial Map4k4 (show MAP4K4 Antibodies) is critical for lymphatic vascular development by regulating endothelial cells (EC)quiescence and lymphatic EC fate.
of the five variants, SNP rs2236935T/C was significantly associated with type 2 diabetes mellitus (T2DM) in this study population; conclude that MAP4K4 (show MAP4K4 Antibodies) gene is associated with T2DM in a Chinese Han population, and MAP4K4 (show MAP4K4 Antibodies) gene variants may contribute to the risk toward the development of T2DM
The expression of OTUD7B (show OTUD7B Antibodies) and NIK were negatively correlated in non-small cell lung cancer tumor samples. the higher expression of NIK was related to more lymph node metastasis and later TNM (show ODZ1 Antibodies) stage. high OTUD7B (show OTUD7B Antibodies)/low NIK index can predict an good prognosis.
Interactions between MAP4K4 (show MAP4K4 Antibodies) gene variants and environmental factors may contribute to MAP4K4 (show MAP4K4 Antibodies) attenuation in T cells, leading to non-obese T2D.
MAP4K4 (show MAP4K4 Antibodies) promotes the epithelial-mesenchymal transition and invasiveness of hepatocellular carcinoma cells
NIK expression was significantly increased in the tumor tissue of patients with breast carcinoma, which may be an important factor that affects the prognosis of these patients.
miR (show MLXIP Antibodies)-194 regulated the progression of hepatocellular carcinoma through directly inhibiting the expression of MAP4K4 (show MAP4K4 Antibodies)
The results of the present study suggested that inhibition of MAP4K4 (show MAP4K4 Antibodies) may be a therapeutic strategy for gastric cancer.
This study identified two novel independent loci (MAP3K14 and CARD9 (show CARD9 Antibodies)) strongly associated with joint damage in Mexican Americans and European Americans and a few shared loci showing suggestive evidence for association.
NIK (show MAP4K4 Antibodies) pathways in both hepatocytes and immune cells act in concert to promote liver steatosis and glucose production in the setting of obesity.
this study demonstrates that although NIK (show MAP4K4 Antibodies) is dispensable for thymocyte development, it has a cell-intrinsic role in regulating the homeostasis and function of peripheral T cells
Using a novel conditional mutant of NIK (show MAP4K4 Antibodies), the authors could show in vivo that NIK (show MAP4K4 Antibodies) signaling in thymic epithelial cells is essential for the thymic hardwiring of gammadelta T cell cytokine production.
NIK (show MAP4K4 Antibodies) not only contributes to lymphoid organogenesis, inflammation and cell survival but also to TNFR1 (show TNFRSF1A Antibodies)/RIP1 (show RALBP1 Antibodies)-dependent cell death independently of the alternative NF-kappaB (show NFKB1 Antibodies) pathway.
This study demonstrated that NFkappaB-inducing kinase inhibits NFkappaB activity specifically in neurons of the CNS.
results assign NIK (show MAP4K4 Antibodies)-induced alternative NF-kappaB (show NFKB1 Antibodies) signaling a master regulatory role in B-cells, starting from the T1 stage and also show that B-1 B cells are less dependent on this pathway, presumably owing to the existence of alternative pathways yet to be determined
NIK (show MAP4K4 Antibodies), and thus probably the noncanonical NF-kappaB (show NFKB1 Antibodies) pathway, is critical to allow DCs to acquire the capacity to cross-present antigen and prime CD8 (show CD8A Antibodies) T cells after exposure to licensing stimuli.
Deletion of NIK (show MAP4K4 Antibodies) in adult mice results in decreases in B cell populations in lymph nodes and spleen, similar to what is observed upon blockade of BAFF (show TNFSF13B Antibodies).
We identify NIK (show MAP4K4 Antibodies) as a critical negative regulator of beta cell function, as pharmacological NIK (show MAP4K4 Antibodies) activation results in impaired glucose-stimulated insulin (show INS Antibodies) secretion in mouse and human islets.
the NIK (show MAP4K4 Antibodies) in thymic stroma may be critically involved in the differentiation of most NKT (show CTSL1 Antibodies) cell subsets (although the level of NIK (show MAP4K4 Antibodies) dependence may vary among the subsets), and also the NIK (show MAP4K4 Antibodies) in NKT (show CTSL1 Antibodies)-alphabeta cells may be dispensable for their effector function.
The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase has been shown to specifically activate MAPK8/JNK. The activation of MAPK8 by this kinase is found to be inhibited by the dominant-negative mutants of MAP3K7/TAK1, MAP2K4/MKK4, and MAP2K7/MKK7, which suggests that this kinase may function through the MAP3K7-MAP2K4-MAP2K7 kinase cascade, and mediate the TNF-alpha signaling pathway. Alternatively spliced transcript variants encoding different isoforms have been identified.
, serine/threonine protein-kinase
, serine/threonine-protein kinase NIK
, HPK/GCK-like kinase HGK
, MAPK/ERK kinase kinase kinase 4
, MEK kinase kinase 4
, Ste20 group protein kinase HGK
, hepatocyte progenitor kinase-like/germinal center kinase-like kinase
, nck-interacting kinase
, NF kappa B-inducing kinase
, Nfkb inducing kinase
, protein kinase